All mechanism

systematic review meta-analysis network meta-analysis

Select diabetic kidney diseaseheart failure with preserved LVEF melanomamultiple myelomaobesity and overweight adjuvant settinguncoded clinical condition ***All type of patientnewly diagnosed--- uncoded (null)       angiotensin receptor blockerangiotensin receptor neprilysin inhibitorAngiotensin-Converting Enzyme Inhibitorsanti-CTLA-4anti-PD-1BRAF inhibitorBupropioncalcium-channel blockerscarfilzomibcombined BRAF and MEK inhibitionFluoxetineglucagon-like peptide-1interferonlipase inhibitormineralocorticoid receptor antagonistsphentermine and topiramateserotonin 5HT2C-receptor agonistserotonin-norepinephrine reuptake inhibitortesofensineTopiramate atorvastatinamlodipineperindoprilramiprilirbesartanlosartancandesartanInterferon alphatrametinib + dabrafenib vemurafenibAmbrisentanamitriptylineberaprostbosentanBupropionepoprostenolfinerenoneiloprostipilimumabliraglutidelorcaserinnivolumabolmesartanorlistatpembrolizumabphentermine and topiramateSibutramine terbogreltopiramate vs anti-CTLA-4vs placebo or controlvs placebo or no treatmentvs angiotensin-converting enzyme inhibitorsvs calcium-channel blockers       adjuvant

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (35)hyperhemia or ocular redness (23)progression or death (progression free survival PFS) (14)death (overall survival) (13)amélioration globale (patient) (12)Cardiovascular death (10)Hospitalization for any reason (9)cardiovascular events (9)stroke (fatal and non fatal) (7)microvascular events (5)distant metastasis free survival (5)amélioration globale (clinicien) (4)myocardial infarction (fatal and non fatal) (4)hospitalisation for heart failure (3)weight loss equal to or greater than 5 percent (3)weight loss equal to or greater than 10 percent (3)IOP change at 3 mo, absolute (mmHg) (3)Coronary event (3)Non fatal MI (3)Grade 3–5 drug-related AEs (3)recurrence free survival (3)Cardiovascular death or hospital admission for CHF (2)MACE (2)Non fatal stroke (2)death or cardiovascular hospitalization (1)Death from any cause or hospitalization for any reason (1)Long term death (1)IOP at 3 months (mmHg) (1)Death from cancer (1)Myopathy (1)Rhabdomyolysis (1)Adverse events (1)Fatal stroke (1)Haemmorhagic stroke (1)non cardiovascular death (1)Heart failure (1)vitiligo any grade (1)vitiligo grade 3-4 (1)Adverse events leading to treatment discontinuation (1)aaa (1)Coronary death (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	hyperhemia or ocular redness
diabetic kidney disease
amlodipine
IDNT (amlodipine vs PBO), 2001	amlodipine	placebo			Low risk of bias	negative
irbesartan
IPDM (150mg), 2001	irbesartan	placebo			Low risk of bias	suggesting
IDNT (irbesartan vs pbo), 2001	irbesartan	placebo			Low risk of bias	suggesting
IDNT (irbesartan vs amlodipine), 2001	irbesartan	amlodipine			Low risk of bias	suggesting
losartan
RENAAL, 2001	losartan	placebo			Low risk of bias	suggesting
olmesartan
ORIENT    NCT	olmesartan	placebo			Low risk of bias	negative
ramipril
DIABHYCAR, 2004	ramipril	placebo			Low risk of bias	negative
heart failure with preserved LVEF
candesartan
CHARM preserved, 2003	candesartan	placebo			Low risk of bias	-
irbesartan
I-PRESERVE (McMurray), 2008      NCT	ibesartan	placebo			Low risk of bias	negative
perindopril
PEP CHF, 2006	perindopril	placebo			Low risk of bias	negative
melanoma
Interferon alpha
Nordic IFN Trial, 2011	ID IFN alpha-2b (I M)	observation	adjuvant			suggesting
EORTC18952 (Eggermont), 2005	ID IFN alpha-2b (I M)	observation	adjuvant			negative
EORTC18991 (Eggermont), 2008	PEG IFN alpha-2b (I M)	observation	adjuvant			suggesting
EORTC18871/DKG 80-1 (Kleeberg), 2004	rIFN alpha-2b	observation	adjuvant			negative
ipilimumab
EORTC 18071 (Eggermont), 2015        NCT	ipilimumab	placebo	adjuvant	adjuvant	Low risk of bias	conclusive
nivolumab
CheckMate 238, 2017      NCT	nivolumab	ipilimumab	adjuvant	adjuvant	Low risk of bias	conclusive
pembrolizumab
KEYNOTE-054, 2018      NCT	pembrolizumab	placebo	adjuvant	adjuvant	Low risk of bias	conclusive
trametinib + dabrafenib
COMBI-AD, 2017      NCT	trametinib and dabrafenib	placebo	adjuvant		Low risk of bias	suggesting
COMBI neo, 2018      NCT	trametinib and dabrafenib	SOC	adjuvant			-
vemurafenib
BRIM 8, 2018      NCT	vemurafenib	placebo	adjuvant			suggesting
obesity and overweight
Bupropion
Anderson, 2002	Bupropion	placebo			Low risk of bias	-
Croft, 2002	Bupropion	placebo				-
Jain, 2002	Bupropion	placebo			Low risk of bias	-
liraglutide
Astrup (NN8022-1807 ), 2009    NCT	liraglutide	placebo			Low risk of bias	-
lorcaserin
BLOSSOM (10mg bid), 2009      NCT	lorcaserin	placebo			Low risk of bias	-
BLOOM, 2010    NCT	lorcaserin	placebo			Low risk of bias	-
BLOOM-DM (10mg bid)    NCT	lorcaserin	placebo			Low risk of bias	-
orlistat
Muls, 2001	Orlistat	placebo			Low risk of bias	-
Naumov, 2002	Orlistat	placebo				-
Rissanen, 2001	Orlistat	placebo			Low risk of bias	-
Rosenfalck, 2002	Orlistat	placebo				-
Rossner, 2000	Orlistat	placebo			Low risk of bias	-
Shi Yi, 2001	Orlistat	placebo				-
Sjostrom, 1998	Orlistat	placebo			Low risk of bias	-
Vidgren, 1999	Orlistat	placebo				-
Broom,, 2001	Orlistat	placebo				-
Bakris, 2002	Orlistat	placebo			Low risk of bias	-
Broom, 2002	Orlistat	placebo			Low risk of bias	-
Davidson, 1999	Orlistat	placebo			Low risk of bias	-
Deerochanawong,, 2001	Orlistat	placebo				-
Derosa, 2003	Orlistat	placebo			Low risk of bias	-
Gotfredsen, 2001	Orlistat	placebo				-
Halpern, 2003	Orlistat	placebo			Low risk of bias	-
Hanefeld, 2002	Orlistat	placebo				-
Hauptman, 2000	Orlistat	placebo			Low risk of bias	-
Hill, 1999	Orlistat	placebo			Low risk of bias	-
Reaven, 2001	Orlistat	placebo				-
Hollander, 1998	Orlistat	placebo				-
Karhunen, 2000	Orlistat	placebo				-
Kelley, 2002	Orlistat	placebo			Low risk of bias	-
Krempf, 2005	Orlistat	placebo				-
Lindgarde, 2000	Orlistat	placebo				-
Lucas, 2003	Orlistat	placebo				-
Micic, 1999	Orlistat	placebo			Low risk of bias	-
Miles, 2002	Orlistat	placebo			Low risk of bias	-
phentermine and topiramate
CONQUER (high-dose) (OB 303)      NCT	PHEN/TPM high dose	placebo				-
OB 302 (high-dose)	PHEN/TPM high dose	placebo				-
OB 301 (high-dose)	PHEN/TPM high dose	placebo				-
OB 302 (low-dose)	PHEN/TPM low-dose	placebo				-
OB 301 (mid-dose)	PHEN/TPM mid-dose	placebo				-
CONQUER (mid-dose) (OB 303)      NCT	PHEN/TPM mid-dose	placebo				-
Sibutramine
McMahon, 2000	Sibutramine	placebo				-
McMahon, 2002	Sibutramine	placebo				-
Smith, 2001	Sibutramine	placebo				-
SCOUT, 2010        NCT	sibutramine	placebo			Low risk of bias	-
topiramate
Tonstad, 2003	Topiramate	placebo				-
Caterson, 2003	Topiramate	placebo				-
Bray, 2003	Topiramate	placebo				-
Pud’homme, 2003	Topiramate	placebo				-
Rissanen, 2003	Topiramate	placebo				-
Stenlof, 2003	Topiramate	placebo				-